Nanexa

Nanexa Financial Leverage

The Financial Leverage (Equity Multiplier) of Nanexa (NANEXA.ST) as of Oct 23, 2026 is 1.36. In the previous year, Financial Leverage (Equity Multiplier) was 1.29 — a change of 5.10% (higher).

Financial Leverage

1.36

YoY

5.10%

Last updated:

Financial Leverage (Equity Multiplier) of Nanexa is 2025 1.36 . Financial Leverage (Equity Multiplier) of Nanexa was 2024 1.29 . It decreases by 5.10% higher compared to the previous year.

The Nanexa Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.71 SEK
Jan 1, 2019
1.42 SEK
Jan 1, 2020
1.24 SEK
Jan 1, 2021
1.09 SEK
Jan 1, 2022
1.56 SEK
Jan 1, 2023
1.38 SEK
Jan 1, 2024
1.29 SEK
Jan 1, 2025
1.36 SEK
The Nanexa Financial Leverage history
YEARFinancial LeverageYoY
1.36+5.10%
1.29-6.20%
1.38-11.53%
1.56+43.05%
1.09-11.95%
1.24-13.05%
1.42-16.84%
1.71+41.81%
1.21-0.48%
1.21-5.55%
1.28-27.02%
1.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanexa Stock analysis

What does Nanexa do? Nanexa AB develops and distributes medical nanotechnology products including PharmaShell, a drug delivery system for targeted dosing, and antifungal coating that protects medical products from fungal growth. The company also offers low-friction coating for peripheral venous catheters. Its products are sold to healthcare providers and medical device manufacturers seeking advanced solutions for drug delivery and infection prevention. Nanexa AB's revenue comes from the sale of its nanotechnology-based products to healthcare institutions and medical device companies. The firm focuses on life science R&D, targeting applications in pharmaceuticals and medical device manufacturing. Its product portfolio serves the healthcare sector by enhancing drug efficacy and protecting medical equipment from microbial contamination. The company's business model relies on selling specialized coatings and delivery systems to medical professionals and manufacturers. PharmaShell enables precise drug targeting, while antifungal and low-friction coatings address specific clinical needs in medical device usage. These products are designed to improve patient outcomes and reduce complications in medical treatments. Nanexa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanexa stock

Financial Leverage (Equity Multiplier) of Nanexa is 1.36 in 2025.

Financial Leverage (Equity Multiplier) of Nanexa changed from 1.29 to 1.36, representing a 5.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Nanexa since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Nanexa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Nanexa

All Key Metrics — Nanexa